Advancing the Field of Eye Care, One Clinical Trial at a Time
Research at EyeCare Partners
EyeCare Partners is committed to innovation and elevating eye care for everyone. ECP is home to world-renowned centers of eye care excellence and leaders from every specialty and subspecialty. The eye doctors and research staff at ECP have been conducting clinical research for more than 35 years and have participated in over 500 research studies. Our goal is to pave the way for tomorrow’s eye care and bring it to our patients today.
The EyeCare Partners practices are always participating in numerous studies across various sub-specialties for adults. Most commonly our clinical research studies are for dry eyes, glaucoma, cataracts, macular degeneration, diabetes, and more. Explore our current clinical research studies with open enrollment and complete the form to learn more about taking part.
Current Clinical Research Studies
Kansas
Stiles EyeCare Excellence
Elios
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the ELIOS System to Reduce Intraocular Pressure in Patients With Primary Open-Angle Glaucoma Undergoing Cataract Surgery
iSTAR
A Prospective, Multicenter Masked Clinical Trial to Evaluate the Safety and Effectiveness of the MINIject CS627 Implant in Subjects With Open Angle Glaucoma
Abbvie
A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Ab Externo Implantation of Glaucoma Gel Stent
Grene Vision Group
Not Enrolling Trials Currently
Missouri
Ophthalmology Associates
Claris Bio
Study To Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Stages 2 and 3 in Neurotrophic Keratitis Subjects
Sylentis
Tivanisiran for Dry Eye in Subjects With Sjögren’s Syndrome
New World Medical
A Prospective, Randomized, Multi-center Evaluation of the Safety and Effectiveness of the STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma
KOWA
A Phase 3, Prospective, Double-masked, Randomized, Multi-center, Vehicle-controlled, Parallel-group, 12-week Administration and 40-week extension Study Confirming the Efficacy and Safety of K-161 Ophthalmic Solution for the treatment of Moderate to Severe Dry Eye Disease.
Trefoil
A Phase 2 Clinical Trial to Assess the Safety and Observe the Potential Benefit of TTHX1114 Delivered via Intra-Cameral (IC) Injection
Ophthalmology Consultants
Oculis
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Elios
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the ELIOS System to Reduce Intraocular Pressure in Patients With Primary Open-Angle Glaucoma Undergoing Cataract Surgery
Texas
EyeCare Associates of East Texas
Opthea
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
Florida
Eye Institute of West Florida
Nicox
Protocol NCX-470-03: A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension (Denali)
RxSight
RXSIGHT LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD) NEW ENROLLMENT STUDY
Visus
Phase 3 Safety and Efficacy Study with a 6-Month Extension of BRIMOCHOL™ PF (Carbachol 2.75% / Brimonidine Tartrate 0.1% Fixed-Dose Combination) Topical Ophthalmic Solution vs. Carbachol PF 2.75% Monotherapy Topical Ophthalmic Solution vs. Vehicle in Subjects with Emmetropic Phakic or Pseudophakic Presbyopia
Virginia
Retina Institute of Virginia
Ionis
A Phase 2, Randomized, Placebo Controlled, Double Masked Study to Assess the Safety and Efficacy of Multiple Doses of IONIS-FB-Lrx, an Antisense Inhibitor of Complement Factor B, In Patients with Geographic Atrophy Secondary to Age Related Macular Degeneration (AMD)
RegenxBio
A Randomized, partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.
Virginia Eye Consultants
Claris
A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Soultion 0.1% in Stage 2 and 3 Neurotrophic Keratitis Subjects.
KOWA
A Phase 3, Prospective, Double-masked, Randomized, Multi-center, Vehicle-controlled, Parallel-group, 12-week Administration and 40-week extension Study Confirming the Efficacy and Safety of K-161 Ophthalmic Solution for the treatment of Moderate to Severe Dry Eye Disease.
Tarsier
A Phase 3 Randomized, Active-Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the Treatment of Subjects with Active Non-infectious Anterior Uveitis including Subjects with Uveitic Glaucoma.
Johnson&Johnson Surgical Vision
Clinical Investigation of the Bacterially-Derived Healon EndoCoat PRO Ophthalmic Viscosurgical Device (OVD)
Kentucky
Retina Associates of Kentucky
Not Enrolling Trials Currently
Bennett and Bloom
Jaeb Center for Health Research
Diabetes Endothelial Keratoplasty Study (DEKS): Impact of Diabetes on Corneal Transplant Success and Endothelial Cell Loss
The Ophthalmology Group
RxSight
Clinical Outcomes of Patients Bilaterally Implanted with Commercially Available RxSight Light Adjustable Lens (LAL)
Indiana
John Kenyon
RegenxBio
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical study to Evaluate the Efficacy & Safety of RGX-314 Gene Therapy in Participants with NAMD
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in participants with nAMD
Alexion
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Ohio
Cincinnati Eye Institute
RegenxBio
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical study to Evaluate the Efficacy & Safety of RGX-314 Gene Therapy in Participants with NAMD
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in participants with nAMD
Gyroscope
A Phase 2, Outcomes Assessor-Masked, Multicentre, Randomized Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Alimera
A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients with Early Diabetic Macular Edema (DME)
Oxurion
A Phase 2, randomized, multicenter study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular edema (DME)
Genentech
A PHASE IIa MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO OPTIMIZE SUBRETINAL SURGICAL DELIVERY AND TO EVALUATE SAFETY AND ACTIVITY OF OPREGEN IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Alcon
The Hydrus Microstent New Enrollment Post-Approval Study: A Prospective, Non-randomized, Multicenter, Single Arm, Clinical Trial (Confirm)
The Hydrus Microstent for IOP Reduction in Mild to Moderate Open-Angle Glaucoma (FRONTIER)
Trefoil
A Phase 2 Clinical Trial to Assess the Safety and Observe the Potential Benefit of TTHX1114 Delivered via Intra-Cameral (IC) Injection
Laboratoires Thea
Efficacy and Safety assessment of T4032 vs Lumigan 0.01% in ocular hypertensives or glaucomatous patients
KOWA
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Treatment and 14-week Extension, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery
Oculis
A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of OCS-01 eyedrops compared to Vehicle in the Treatment of Inflammation and Pain Following Cataract Surgery” to evaluate OCS-01 (Dexamethasone Ophthalmic Suspension,1.5% (15 mg/mL)
CVP Physicians Dayton
Opthea
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
Retina Vitreous Associates
EyePoint Pharmaceuticals
Phase 4 Study of YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis (Intraocular Inflammation) Study
Michigan
Associated Retinal Consultants
RegenxBio
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical study to Evaluate the Efficacy & Safety of RGX-314 Gene Therapy in Participants with NAMD
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in participants with nAMD
Cleveland Clinic/Allergan
Prospective Randomized Comparative Trial for Combination Dexamethasone Implant With PRN Anti-VEGF Therapy To Anti-VEGF Therapy Alone In Treatment Resistant Diabetic Macular Edema: Informing The Role For Imaging Biomarkers and Combination Therapy.
Adverum
Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients With Neovascular (Wet) Age-Related Macular Degeneration.
Vitreo-Retinal Associates
DRCR
Protocol AF: Randomized Trial Evaluating Fenofibrate for
Prevention of Diabetic Retinopathy Worsening
Oakland Ophthalmic Surgery
Not Enrolling Trials Currently
Meet Our Clinical Research Team
Megan Kingdon
Director of Clinical Research – EyeCare Partners
How Does Clinical Research Help Our Patients?
Thousands of patients with eye problems come to an EyeCare Partners practice each week to find leading-edge solutions to their eye care needs. Our participation in clinical research allows us to offer patients the most advanced treatment options possible.
Staying on the Leading Edge of Eye Care Research
Our ongoing commitment to physician- controlled eye care research enables us:
- To provide patients with new and improved treatment options
- To be at the forefront of vision care advances
- To create an environment for lifelong learning and advancement
- To advance the future of eye health and vision